Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000…
By V. Conter, C. Bartram, M. Valsecchi, A. Schrauder, R. Panzer-Grümayer, A. Möricke, M. Aricò, M. Zimmermann, G. Mann, G. de Rossi and 17 more. Blood, 2010
776 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/8e0602fd8f513f47c45cb711e84fb6070a8f1b02
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pediatrics, Perinatology and Child Health
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, background): “completion of initial therapy (or minimal residual disease) has entered routine clinical practice in the management of leukemia.(77) ctDNA can be detected before treatment in patients with earlystage primary cancer; however, ctDNA is generally detected at a lower rate than in advanced cancer.”
- Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. (2015, background): “Among their many collaborative studies, the two groups recently confirmed that minimal residual disease (MRD) assessment is the most prognostic indicator in both Band T-cell ALL.(19,20) They were also instrumental in developing the Intercontinental BFM (IC-BFM) Study Group comprising study groups fr”